Rapamycin and rapalogs for tuberous sclerosis complex (Q26471128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

0 references

1 reference

title

Rapamycin and rapalogs for tuberous sclerosis complex (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Nur Farrah Dila Ismail

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Zamh Zabidi-Hussin

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

13 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

CD011272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin and mTOR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Molecular genetic advances in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Lymphangioleiomyomatosis screening in women with tuberous sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Identification and characterization of the tuberous sclerosis gene on chromosome 16

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

National Institutes of Health consensus conference: tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Matrix metalloproteinases and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberous sclerosis: from tubers to mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Topical rapamycin (sirolimus) for facial angiofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rapamycin reduces seizure frequency in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Multifocal micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Genetics and molecular biology of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Treatment of intractable epilepsy in tuberous sclerosis complex with everolimus is not yet evidence-based.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Akt regulates growth by directly phosphorylating Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Proteins interacting with the tuberous sclerosis gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Rhabdomyomas and tuberous sclerosis complex: our experience in 33 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Causes of Death in Patients With Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Regression of a cardiac rhabdomyoma in a patient receiving everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011272.PUB2

Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation

21 January 2018

1 reference

12 December 2020

Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat

1 reference

12 December 2020

Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex

1 reference

12 December 2020

Renal tumors in postmortem material

1 reference

12 December 2020

Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex

1 reference

12 December 2020

Epidemiology of tuberous sclerosis

1 reference

12 December 2020

Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis

1 reference

12 December 2020

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity

1 reference

12 December 2020

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis

1 reference

12 December 2020

Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex

1 reference

12 December 2020

Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response

1 reference

12 December 2020

Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis

1 reference

12 December 2020

Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86

1 reference

12 December 2020

First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex

1 reference

12 December 2020

Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.

1 reference

12 December 2020

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

1 reference

12 December 2020

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial.

1 reference

12 December 2020

10.1002/14651858.CD011272.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

27409709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27409709%20AND%20SRC:MED&resulttype=core&format=json